Amylyx Pharmaceuticals
AMLX
26.02
-0.18
-0.69%
Amylyx Pharmaceuticals
US · AMLX
#2392 by market cap
Listed 2022
26.02
-0.18
-0.69%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 14 in the most recent period (2026/Q3).
- Total institutional ownership fell 8.9 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 97.75% -8.92pp
- Institutions
- 254 +14
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund57.72%
Hedge Fund19.65%
VC/PE Fund13.96%
Individual/Insider5.91%
Public Company4.37%
Private Company1.22%
Endowment Fund0.26%
Government Pension Fund0.24%
Insurance Company0.20%
Sovereign Wealth Fund0.13%
Other1.97%
Top holders as of 2026-09-30
FMR
15.51% · 19.95M sh
BlackRock
8.06% · 10.37M sh
Perceptive Advisors LLC
6.48% · 8.33M sh
TCG Crossover Management, LLC
4.86% · 6.24M sh
Commodore Capital LP
4.39% · 5.65M sh
Janus Henderson Group plc
4.07% · 5.24M sh
Vanguard Capital Management, LLC
3.95% · 5.08M sh
Saturn V Capital Management LP
3.60% · 4.62M sh
Franklin Resources
3.06% · 3.93M sh
Justin Klee
2.51% · 3.15M sh
Joshua Cohen
2.45% · 3.15M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 28 sells
| Name | Role | Stake |
|---|---|---|
| Joshua Cohen | Co-Chief Executive Officer | 2.45% |
| Justin Klee | Co-Chief Executive Officer | 2.45% |
| George Milne | Independent Chairperson | 0.61% |
| James Frates | Chief Financial Officer | 0.18% |
| Karen Firestone | Independent Director | 0.09% |
| Camille Bedrosian | Chief Medical Officer | 0.08% |
| Gina Mazzariello | Chief Legal Officer & General Counsel | 0.04% |
| Bernhardt G. Zeiher | Independent Director | 0.01% |
| Daphne Quimi | Independent Director | 0.00% |
| Paul Fonteyne | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | James Frates | Chief Financial Officer | Derivative Exercise and Sale | -40,000 | $6.88–30.97 |
| 2026-11-08 | Joshua Cohen | Co-Chief Executive Officer | Automatic Disposition | -100,000 | $29.39–30.11 |
| 2026-11-08 | Justin Klee | Co-Chief Executive Officer | Automatic Disposition | -100,000 | $29.39–30.11 |
| 2026-10-04 | George Milne | Independent Chairperson | Automatic Disposition | -30,000 | $27.70 |
| 2026-09-09 | James Frates | Chief Financial Officer | Private Disposition | -1,042 | $33.23 |
| 2026-09-09 | James Frates | Chief Financial Officer | Open Market Disposition | -9,768 | $32.27 |
| 2026-09-09 | Camille Bedrosian | Chief Medical Officer | Private Disposition | -2,081 | $33.09 |
| 2026-09-09 | Camille Bedrosian | Chief Medical Officer | Open Market Disposition | -7,947 | $32.21 |
| 2026-09-09 | Joshua Cohen | Co-Chief Executive Officer | Private Disposition | -919 | $33.15 |
| 2026-09-09 | Joshua Cohen | Co-Chief Executive Officer | Open Market Disposition | -29,545 | $32.16 |
| 2026-09-09 | Justin Klee | Co-Chief Executive Officer | Private Disposition | -1,439 | $33.16 |
| 2026-09-09 | Justin Klee | Co-Chief Executive Officer | Open Market Disposition | -29,025 | $32.13 |
| 2026-09-09 | Gina Mazzariello | Chief Legal Officer & General Counsel | Private Disposition | -11 | $33.34 |
| 2026-09-09 | Gina Mazzariello | Chief Legal Officer & General Counsel | Open Market Disposition | -9,525 | $32.46 |
| 2026-08-30 | Karen Firestone | Independent Director | Derivative Exercise and Retained | +50,000 | $1.76–5.05 |
| 2026-08-17 | James Frates | Chief Financial Officer | Other Acquisition | +22,807 | -- |
| 2026-08-17 | Camille Bedrosian | Chief Medical Officer | Other Acquisition | +22,807 | -- |
| 2026-08-17 | Joshua Cohen | Co-Chief Executive Officer | Other Acquisition | +60,039 | -- |
| 2026-08-17 | Justin Klee | Co-Chief Executive Officer | Other Acquisition | +60,039 | -- |
| 2026-08-17 | Gina Mazzariello | Chief Legal Officer & General Counsel | Other Acquisition | +21,284 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.
Amylyx Pharmaceuticals discussion 0 comments